NNNN
Anbio Biotechnology
5.60$
-11.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q4 23 | Q2 24 | Q4 24 | Q2 25 | Q3 25 | Q1 26 |
|---|---|---|---|---|---|---|---|
| – | +19.5% | +60.0% | -60.0% | +98.1% | -59.4% | +133.3% | |
| – | +65.6% | -7.2% | -81.4% | -1.6% | -2.2% | +133.3% | |
| – | -12.9% | +149.9% | -49.4% | +116.3% | -64.2% | +133.3% | |
| – | – | -5.3% | +156.1% | -59.4% | -75.6% | +133.2% | |
| – | +172.8% | -69.5% | +1,047.5% | -75.6% | -51.9% | +133.2% | |
| – | -62.0% | +566.3% | -144.6% | – | -67.4% | +133.3% | |
| – | -51.7% | +390.3% | -134.1% | – | -68.6% | +133.3% | |
| – | -51.7% | +390.3% | -134.1% | – | -68.6% | +133.3% | |
| – | -48.5% | +388.1% | -134.1% | – | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.